Plasma Dipeptidyl-peptidase-4 Activities With No-reflow and Bleeding
关键词
抽象
描述
ST-segment elevation myocardial infarction (STEMI) is an acute manifestation of coronary heart disease, remaining a frequent cause of death.A better understanding of risk factors and pathogenic mechanisms underlying STEMI may help improve the prognosis and life quality of these patients.Dipeptidyl peptidase 4 (DPP4) is an exopeptidase expressed on the surface of diverse cells, cleaving off amino-terminal dipeptides with either L-proline, L-alanine or serine at the penultimate position. As a cell surface protein, it participates in immune regulation, signal transduction and apoptosis. DPP4 also circulates as a soluble form in the plasma. Soluble DPP4 came from either membrane type clearance or secreted by cells like endothelial cells, with enzymatic activity. Plasma DPP4 activity (DPP4a) are elevated in several diseases, including type 2 diabetes, obesity, atherosclerosis and osteoporosis. Basic studies have showed that DPP4 inhibition leads improved survival and heart function after cardiac ischemia-reperfusion (I/R) injury, and this is partly due to activation of AKT (pAKT), pGSK3 and ANP pathways. Also inhibition of DPP4 can alleviate atherosclerosis and heart failure. Accordingly, one could hypothesize that high DPP4a may worsen myocardial I/R injury, causing poorer cardiovascular outcomes. However, no study has evaluated whether DPP4a is associated with adverse clinical outcomes in STEMI patients.
日期
最后验证: | 06/30/2016 |
首次提交: | 07/23/2016 |
提交的预估入学人数: | 07/25/2016 |
首次发布: | 07/28/2016 |
上次提交的更新: | 07/25/2016 |
最近更新发布: | 07/28/2016 |
实际学习开始日期: | 12/31/2013 |
预计主要完成日期: | 09/30/2015 |
状况或疾病
相
手臂组
臂 | 干预/治疗 |
---|---|
Quartile 1 Quartile 1 of plasma DPP4 activity | |
Quartile 2 Quartile 2 of plasma DPP4 activity | |
Quartile 3 Quartile 3 of plasma DPP4 activity | |
Quartile 4 Quartile 4 of plasma DPP4 activity |
资格标准
有资格学习的性别 | All |
取样方式 | Non-Probability Sample |
接受健康志愿者 | 是 |
标准 | Inclusion Criteria: - a diagnosis of STEMI and needed PCI Exclusion Criteria: - patients with cancer - patients who used DPP4 inhibitor - patients who used GLP1 analogue |
结果
主要结果指标
1. a change in the prevalence of no-reflow [immediately after PCI]
次要成果指标
1. in-hospital major adverse cardiac or cerebrovascular events [up to 2 week after PCI (until discharge)]
2. in-hospital complications [up to 2 week after PCI (until discharge)]
3. in-hospital major bleeding [up to 2 week after PCI (until discharge)]